Written By | Health News Agencies
A 230-Year-Old "Witch's Weed" Remedy Is Roaring Back Into Heart Failure Wards — And New Data Says It Cuts Hospitalizations by a Quarter
Search
HEALTH
For decades, it sat in the back of the medicine cabinet, half-forgotten and mildly feared — a drug so old it was first prescribed by a British doctor treating dropsy with a purple flower in 1785, and so dangerous in the wrong hands that generations of cardiologists were trained to phase it out the moment something newer came along. Now digoxin, the foxglove-derived heart drug that costs less than a cup of gas-station coffee per day, is staging a comeback that has stunned even the researchers who ran the trials.
A landmark pooled analysis of more than 9,000 heart failure patients, released this month and amplified in a fresh wave of coverage on August 14, 2026, found that low-dose digoxin cut the risk of hospitalization for worsening heart failure by roughly 25 percent when added to standard modern therapy. For a drug that costs pennies a day — compared with the thousands of dollars a year patients can pay for newer heart failure medications — the finding has cardiologists asking an uncomfortable question: did medicine give up on digoxin too soon?
"In patients with heart failure and reduced or mildly reduced ejection fraction, low-dose digitalis glycosides appear to be an effective, inexpensive, safe, and easy-to-use adjunctive pharmacological treatment option," said Dr. Dirk van Veldhuisen, the cardiologist at University Medical Centre Groningen who led the pivotal DECISION trial, one of the three studies behind the new numbers. "The data support the role of low-dose digoxin in the current management of heart failure, although caution is advised when discontinuing it."
That last line is not a throwaway. It hints at a twist buried inside the data — more on that below.
FROM POISON GARDEN TO PRESCRIPTION PAD
Digoxin's backstory reads like something out of a Victorian apothecary's diary, because in a sense, it is one. The drug is derived from digitalis, the purple foxglove plant — a flower so toxic in its raw form that folk healers called it "witch's bells" and "dead man's fingers." In 1785, English physician William Withering published an account of using foxglove extract to treat dropsy (what we now call fluid retention from heart failure), effectively founding modern cardiac pharmacology in the process.
For the next two centuries, digoxin — the purified, standardized descendant of Withering's foxglove tea — became a mainstay of heart failure treatment. It works by inhibiting a cellular pump called Na+/K+-ATPase, which increases the amount of calcium available inside heart muscle cells. The result is a modest but real increase in the force of each heartbeat, along with effects that help control heart rate, particularly in patients with atrial fibrillation.
But digoxin has always had a dark side: a notoriously narrow therapeutic window. Too little and it does nothing; too much and it can trigger nausea, visual disturbances, and life-threatening arrhythmias. The landmark DIG trial, published in 1997 and involving nearly 6,800 patients, found that digoxin reduced heart failure hospitalizations but had no effect on overall mortality — and post-hoc analyses suggested that patients with higher blood levels of the drug actually had worse outcomes. As newer, safer, and more profitable drug classes emerged — ACE inhibitors, beta-blockers, ARNIs, SGLT2 inhibitors — digoxin was quietly shuffled toward the exit. By the 2010s, many cardiology fellows were being trained to view it as a relic, a drug you inherited from a patient's decades-old prescription list rather than one you'd newly initiate.
THE COMEBACK: THREE TRIALS, ONE BIG SIGNAL
The rehabilitation of digoxin's reputation didn't happen overnight. It came from a deliberate, multi-year research effort culminating in three trials — DIG, DIGIT-HF, and the newly completed DECISION trial — that were pooled together into a meta-analysis led by Dr. Kevin Damman and colleagues, published in JAMA and presented at the Heart Failure 2026 congress of the European Society of Cardiology.
The centerpiece of the new evidence is DECISION (Digoxin Evaluation in Chronic heart failure: Investigational Study In Outpatients in the Netherlands), a double-blind, placebo-controlled trial run across 43 sites in the Netherlands. Researchers enrolled 1,001 patients with symptomatic chronic heart failure and a left ventricular ejection fraction of 50 percent or less — meaning their hearts were pumping less efficiently than a healthy heart should. Patients were randomized to receive either low-dose digoxin, carefully titrated to a target serum concentration of just 0.5 to 0.9 nanograms per milliliter (well below the levels associated with toxicity in older studies), or a placebo. They were followed for a median of 36.5 months — just over three years.
On its own, DECISION's headline result was a near-miss: the trial did not find a statistically significant reduction in its primary composite endpoint of total worsening heart failure events and cardiovascular death. But there were numerically fewer events in the digoxin group, and crucially, the drug proved remarkably safe at these carefully controlled low doses. Serious treatment-related adverse events occurred in 40 patients on digoxin versus 25 on placebo — a difference that did not reach statistical significance, according to the trial's published results in the European Heart Journal and Nature Medicine.
The real story emerged when DECISION's data was combined with the older DIG trial and the more recent DIGIT-HF study in the JAMA meta-analysis. Across the pooled cohort of 9,013 patients, digitalis glycoside treatment reduced the risk of the combined endpoint of cardiovascular death or a first worsening heart failure event by a hazard ratio of 0.85 (95% CI, 0.80–0.90; p<0.001) — a result that easily cleared the bar for statistical significance. Crucially, researchers found the benefit was "driven mainly by fewer worsening-heart-failure events," which is where the now-viral "25 percent fewer hospitalizations" figure comes from.
"New positive data on old drugs: Digitalis reduces heart failure events," read the headline the European Society of Cardiology used in its own press release summarizing the findings — about as close to an institutional victory lap as cardiology press releases get.
THE MONEY ANGLE: PENNIES VS. THOUSANDS
Part of what's fueling the tabloid-ready buzz around this story is the sheer price gap. A month's supply of generic digoxin can run patients well under $10 in the United States — often just a few cents per daily dose, especially through discount generic programs. Compare that to newer heart failure "pillars" like SGLT2 inhibitors (brand names including Farxiga and Jardiance) or ARNIs (Entresto), which can cost patients hundreds to over a thousand dollars a month before insurance, and thousands annually even with coverage.
For health systems drowning in the cost of heart failure care — one of the most expensive chronic conditions in American medicine, responsible for over a million hospitalizations a year in the U.S. alone — the idea that a decades-old, dirt-cheap pill could meaningfully reduce readmissions is the kind of headline that writes itself: "This 10-cent heart drug cuts hospitalizations by 25%," as one widely shared science outlet put it in mid-August coverage of the findings.
To be clear, researchers are not suggesting digoxin replace the modern four-pillar approach to heart failure treatment — beta-blockers, ACE inhibitors/ARBs/ARNIs, mineralocorticoid receptor antagonists, and SGLT2 inhibitors remain the backbone of guideline-directed therapy, and none of the new trials tested digoxin as a substitute for these drugs. Instead, the excitement is about digoxin's potential role as a cheap, effective add-on for patients who are still symptomatic or being readmitted despite being on optimal modern therapy.
THE CAUTION HIDDEN IN THE FOOTNOTES
Here's where van Veldhuisen's warning about "caution when discontinuing it" becomes important, and where the tabloid excitement needs a reality check. Digoxin's narrow therapeutic window hasn't disappeared just because the new trials used lower target doses. Patients on digoxin still need periodic blood tests to monitor serum concentration, and the drug's list of interactions — with common medications including certain diuretics, antibiotics, and antiarrhythmics — remains a real clinical concern, particularly in older patients with reduced kidney function, who process the drug more slowly and are at higher risk of toxicity.
There's also a subtler finding worth flagging: some earlier data, including a post-hoc analysis of the original DIG trial published in the European Heart Journal, found that discontinuing digoxin abruptly in patients who had been stable on it was associated with worse outcomes — a "withdrawal effect" that researchers believe may partly explain why some earlier observational data on digoxin looked confusing or contradictory. It's a reminder that even as digoxin's reputation improves, it is not a drug to start or stop casually, and self-adjusting a digoxin prescription based on a viral headline would be a serious mistake.
EXPERT PERSPECTIVE
Cardiologists reacting to the pooled analysis have generally described the findings as reassuring rather than revolutionary — but reassuring in a way that could genuinely change prescribing habits. Because the low-dose regimen used in DECISION and the pooled analysis kept serum concentrations well below the range associated with toxicity in older studies, several researchers involved in the work have suggested the data could eventually influence heart failure treatment guidelines, potentially reopening the door for wider use of a drug that fell out of favor more because of fear than because of solid evidence of harm at appropriately low doses.
Independent commentary accompanying the JAMA meta-analysis has struck a similar note: digoxin isn't a miracle cure, and it isn't a substitute for the expensive, guideline-recommended medications that have driven real mortality improvements in heart failure over the past 20 years. But as an inexpensive, well-tolerated add-on for the right patients — particularly those still being hospitalized repeatedly despite optimal modern therapy — it may deserve a second look that it hasn't gotten in a generation.
WHAT THIS MEANS FOR YOU
If you or a family member has heart failure with a reduced or mildly reduced ejection fraction and is still experiencing symptoms or repeat hospitalizations despite being on standard medications, this is a reasonable topic to raise at your next cardiology appointment — not a reason to ask a pharmacist for digoxin over the counter, since it remains a prescription drug requiring blood monitoring. If you were previously on digoxin and your doctor took you off it, don't assume this new data means you should quietly resume the old bottle in your cabinet; dosing and monitoring matter enormously, and restarting without medical supervision carries real risk. And if cost is a barrier to your current heart failure regimen, it's worth asking your care team whether a low-dose digoxin add-on — one of the cheapest drugs in cardiology — might be a reasonable option alongside, not instead of, your other medications.
For the roughly 6.7 million American adults living with heart failure, and the many more worldwide, the message from this new wave of data isn't that everything we thought we knew about digoxin was wrong. It's that a drug born from a poisonous garden flower in the 18th century, sidelined by fear of its own toxicity in the 20th, may still have a legitimate — and remarkably cheap — role to play in the 21st.
CONCLUSION
Medicine doesn't often get "throwback" stories with this much data behind them. Digoxin's journey — from foxglove tea to feared toxin to newly rehabilitated, dirt-cheap heart failure ally — is a rare case of an old drug earning its way back into modern guidelines through rigorous, decades-spanning trial work rather than nostalgia. Whether cardiology societies formally update their recommendations remains to be seen, but for now, the message from Groningen, Rotterdam, and the JAMA meta-analysis team is clear: don't throw out the foxglove just yet.
